Researcher
Claus Bachert
- Disciplines:Dermatology
Affiliations
- Department of Head and Skin (Department)
Member
From1 Oct 2018 → Today - Department of Otorhinolaryngology (Department)
Member
From1 Oct 1998 → 30 Sep 2018
Projects
1 - 10 of 30
- Role of IL-33 and SERPINB4 in the exacerbations of airway inflammation, induced by viral- or bacterial-derived pathogensFrom1 Nov 2019 → TodayFunding: FWO Strategic Basic Research Grant
- Protease dependent regulation of IL-33 activity in allergic airway inflammationFrom1 Jan 2019 → TodayFunding: FWO research project
- Understanding Heterogeneity of Eosinophils in Airway DiseaseFrom1 Jan 2018 → 31 Dec 2021Funding: FWO EOS
- Eosinophils in upper airway inflammation : the good, the bad or the ugly? A study on the role of staphylococcus aureus in the interactions and plasticity of eosinophils and their products in upper airway inflammation.From1 Oct 2017 → 30 Sep 2020Funding: FWO fellowships
- Investigation of the role and interaction of eosinophil extracellular traps and Staphylococcus Aureus in chronic rhinosinusitisFrom1 Jan 2016 → 31 Dec 2018Funding: FWO research project
- Peroxisomes in mast cells U+2013 their functions and link to airway inflammationFrom1 Oct 2014 → 30 Sep 2018Funding: FWO fellowships, BOF - Other initiatives
- Identification of immunomodulating factors affecting T cell plasticity in upper airwaysFrom1 Mar 2014 → 30 Nov 2016Funding: BOF - Other initiatives
- The role of peroxisomes in inflammation and cell deathFrom1 Jan 2014 → 31 Oct 2019Funding: BOF - Concerted Research Project from 1994
- Role of purinergic signaling in the pathophysiology of human chronic upper airway inflammationFrom1 Sep 2013 → 28 Feb 2014Funding: BOF - Doctoral projects
- S100A8/A9, HMGB1 and their common receptors in the pathophysiology of human chronic airway inflammationFrom1 Mar 2013 → 31 Dec 2017Funding: BOF - Doctoral projects
Publications
1 - 10 of 607
- Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps : a randomized, placebo-controlled trial(2022)
Authors: Claus Bachert, Joseph K. Han, Martin Y. Desrosiers, Philippe Gevaert, Enrico Heffler, Claire Hopkins, Jody R. Tversky, Peter Barker, David Cohen, Claire Emson, et al.
Pages: 1309 - 1317.e12 - The protease SplB of staphylococcus aureus targets host complement components and inhibits complement-mediated bacterial opsonophagocytosis(2022)
Authors: Prasad Dasari, Maria Nordengrün, Cláudia Vilhena, Leif Steil, Goran Abdurrahman, Kristin Surmann, Vishnu Dhople, Julia Lahrberg, Claus Bachert, Christine Skerka, et al.
Number of pages: 1 - Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patientU+2010reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUSU+201024 and SINUSU+201052 studies(2022)
Authors: Claus Bachert, Anju T. Peters, Enrico Heffler, Joseph K. Han, Heidi Olze, Oliver Pfaar, ChienU+2010Chia Chuang, Raj Rout, Richa Attre, Ledia Goga, et al.
Pages: 244 - 249 - Estimating clinically meaningful change of efficacy outcomes in inadequately controlled chronic rhinosinusitis with nasal polyposis(2022)
Authors: Joseph K. Han, Claus Bachert, Stella E. Lee, Claire Hopkins, Enrico Heffler, Peter Hellings, Anju T. Peters, Siddhesh Kamat, Diane Whalley, Shanshan Qin, et al.
Pages: 265 - 271 - Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUSU+201052 is unaffected by eosinophilic status(2022)
Authors: Shigeharu Fujieda, Shoji Matsune, Sachio Takeno, Nobuo Ohta, Mikiya Asako, Claus Bachert, Tomoyuki Inoue, Yoshinori Takahashi, Hiroyuki Fujita, Yamo Deniz, et al.
Pages: 186 - 196 - Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP and a clinical diagnosis of NSAIDU+2010ERD : results from two randomized placeboU+2010controlled phase 3 trials(2022)
Authors: Joaquim Mullol, Tanya M. Laidlaw, Claus Bachert, Leda P. Mannent, G. Walter Canonica, Joseph K. Han, Jorge F. Maspero, Cesar Picado, Nadia Daizadeh, Benjamin Ortiz, et al.
Pages: 1231 - 1244 - Dupilumab in CRSwNP : responder analysis using clinically meaningful efficacy outcome thresholds(2022)
Authors: ChienU+2010Chia Chuang, Isabelle Guillemin, Claus Bachert, Stella E. Lee, Peter Hellings, Wytske J. Fokkens, Nicolas Duverger, Chunpeng Fan, Nadia Daizadeh, Nikhil Amin, et al.
Pages: 259 - 264 - Physical activity in asthma control and its immune modulatory effect in asthmatic preschoolers(2022)
Authors: Debbie J. Maurer, Chengyao Liu, Paraskevi Xepapadaki, Barbara Stanic, Claus Bachert, Susetta Finotto, YaU+2010Dong Gao, Anna Graser, Tuomas Jartti, Walter Kistler, et al.
Pages: 1216 - 1230 - Early but not late ferroptotic cancer cells are immunogenic in vitro and in vivo(2021)Volume: 11
Authors: Iuliia Efimova, Elena Catanzaro, Louis Van der Meeren, Claus Bachert, Andre Skirtach, Olga Krysko, Dmitri Krysko
Pages: 408 - 408 - ARIA 2019 care pathways for allergic rhinitis in the Kuwait health care system(2021)
Authors: Mona Al-Ahmad, Jasmina Nurkic, Claus Bachert, Oliver Pfaar, Holger J. Schunemann, Wienczyslawa Czarlewski, Anna Bedbrook, Jean Bosquet
Pages: 320 - 330